Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of rhASM in adult patients with Acid Sphingomyelinase Deficiency (ASMD) following repeated-dose administration.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01722526
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 1
Start date March 2013
Completion date January 2014